Christian Marth, ENGOT Chair, AGO-Austria, Andreas du Bois, ENGOT Vice-Chair, AGO Germany, Christian Schauer (AGO-Austria), Andreas du Bois (AGO-Germany), Antonio Casado (EORTC GCG), Ignace Vergote (BGOG), Jose Maria del Campo (GEICO), Athina Goudopoulou (HECOG), Eric Pujade-Lauraine (GINECO), Ilan Bruchim (ISGO), Nicoletta Colombo (ManGO), Sandro Pignata (MITO), Jonathan Ledermann (NCRI/MCR), Radoslav Chekerov (NOGGO), Mansoor Raza Mirza (NSGO), Anneke Westermann (DGOG), Ros Glasspool (SGTCG), Cagatay Taskiran (TSGO), Mathias Fehr (SAKK), and David Cibula (CEEGOG)

10.1097/igc.0000000000000446

Cite

Citations (1)

p53 mutations detection in urinary bladder cancer in the Greek population: application of the NIRCA assay.

PubMed (2003)

Athina Goudopoulou Angelica A. Saetta Penelope Korkolopoulou E Patsouris Galinos Fanourakis

The aim of the present study was to assess the use of an alternative molecular approach for p53 mutation detection and to investigate the usefulness of p53 as a prognostic indicator in bladder cancer. We applied the NIRCA assay, which consists of two-step PCR amplification, transcription of the amplified sequence, hybridisation of the transcripts and treatment with RNAses which recognizes mismatches due to the presence of mutations. Results of molecular analysis are correlated with immunohistochemical findings, standard clinopathological parameters and survival. p53 mutations were detected in 42.4% of the 66 examined TCCs cases. We could not demonstrate any statistical relationship between the presence of p53 mutation and p53 protein overexpression, and tumor stage or grade. A trend towards higher mutation rate in higher grade tumours was observed, although this failed to reach statistical significance. Despite the observation that the alterations of p53 gene are associated features of aggressive phenotype of transitional cell carcinomas they do not seem to offer additional prognostic information.

Source

Cite

Citations (4)

c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations

Urology (2004)

Penelope Korkolopoulou Athina Goudopoulou Gerassimos E. Voutsinas Euphemia Thomas-Tsagli Panagiotis Kapralos

Fas ligand

Flip

10.1016/j.urology.2004.01.007

Cite

Citations (69)

Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid Cancer

Clinical Cancer Research (2005)

Constantine S. Mitsiades Vassiliki Poulaki Ciaran J. McMullan Joseph Negri Galinos Fanourakis

Histone deacetylases (HDAC) and histone acetyltransferases exert opposing enzymatic activities that modulate the degree of acetylation of histones and other intracellular molecular targets, thereby regulating gene expression, cellular differentiation, and survival. HDAC inhibition results in accumulation of acetylated histones and induces differentiation and/or apoptosis in transformed cells. In this study, we characterized the effect of two HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA) and m-carboxycinnamic acid bis-hydroxamide, on thyroid carcinoma cell lines, including lines originating from anaplastic and medullary carcinomas. In these models, both SAHA and m-carboxycinnamic acid bis-hydroxamide induced growth arrest and caspase-mediated apoptosis and increased p21 protein levels, retinoblastoma hypophosphorylation, BH3-interacting domain death agonist cleavage, Bax up-regulation, down-regulation of Bcl-2, A1, and Bcl-x(L) expression, and cleavage of poly(ADP-ribose) polymerase and caspase-8, -9, -3, -7, and -2. Transfection of Bcl-2 cDNA partially suppressed SAHA-induced cell death. SAHA down-regulated the expression of the apoptosis inhibitors FLIP and cIAP-2 and sensitized tumor cells to cytotoxic chemotherapy and death receptor activation. Our studies provide insight into the tumor type-specific mechanisms of antitumor effects of HDAC inhibitors and a framework for future clinical applications of HDAC inhibitors in patients with thyroid cancer, including histologic subtypes (e.g., anaplastic and medullary thyroid carcinomas) for which limited, if any, therapeutic options are available.

Histone deacetylase inhibitor

Vorinostat

Anaplastic thyroid cancer

10.1158/1078-0432.ccr-03-0776

Cite

Citations (90)

Evaluation of the Ras/B-Raf/SHP-2 Axis in B Cell Malignancies.

Blood (2004)

Constantine S. Mitsiades Nicholas Mitsiades Galinos Fanourakis Athina Goudopoulou Ciaran J. McMullan

PTPN11

Noonan Syndrome

10.1182/blood.v104.11.4344.4344

Cite

Citations (0)